A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies
Michael Dickinson(The University of Melbourne), Brian T. Hill(Cleveland Clinic), David Shook(St. Jude Children's Research Hospital), Joanne B.L. Tan(Nkarta Therapeutics (United States)), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Glen Kennedy(Royal Brisbane and Women's Hospital), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Christian Bryant(Royal Prince Alfred Hospital), Nada Hamad(UNSW Sydney), Hongtao Liu(University of Chicago), Peter A. McSweeney(Mesoblast (United States)), Kanya Rajangam(Nkarta Therapeutics (United States))
Cited by 19
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k